Organon & (OGN) ZACKS·2024-10-31 15:30Core Insights - Organon reported revenue of $1.58 billion for the quarter ended September 2024, reflecting a 4.2% increase year-over-year and surpassing the Zacks Consensus Estimate of $1.56 billion by 1.37% [1] - The company's EPS was $0.87, consistent with the same quarter last year, and exceeded the consensus EPS estimate of $0.85 by 2.35% [1] Revenue Performance - Women's Health revenue from Nexplanon/Implanon NXT in the U.S. was $172 million, exceeding the estimated $164.46 million, marking a 17.8% increase year-over-year [3] - U.S. geographic revenue was $398 million, slightly below the estimated $400.64 million, with a year-over-year increase of 7.6% [3] - Revenue from Women's Health NuvaRing was $7 million, significantly lower than the estimated $10.08 million, representing a 61.1% decrease year-over-year [3] - Revenue from Women's Health Follistim AQ was $26 million, slightly above the estimated $25.52 million, with an 18.2% year-over-year increase [3] - Total revenue from Women's Health was $440 million, below the estimated $452.30 million, reflecting a 5.3% increase year-over-year [3] - Total revenue from Biosimilars was $165 million, slightly below the estimated $168.58 million, with a year-over-year increase of 16.2% [3] Stock Performance - Over the past month, Organon shares have returned -3.5%, contrasting with the Zacks S&P 500 composite's +1% change [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [4]